Jazz Pharmaceuticals to acquire Chimerix for $8.55/share in all-cash tender offer

Jazz Pharmaceuticals plc

Tender offer to commence by March 24, 2025; Chimerix board unanimously recommends.
Offer subject to minimum tender condition, HSR clearance, and no material adverse effect.
After tender, merger under DGCL Section 251(h); remaining shares converted at same $8.55.
Amendment No. 1 corrects typographical error in exhibit; no substantive changes to terms.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.